COPD Drug Market Opportunity & Clinical Pipeline Analysis

Close to 1 Billion people worldwide suffer from respiratory or pulmonary diseases. In the respiratory therapeutic domain, Asthma and COPD are the major categories, accounting for close to 75% of the total patient for respiratory or pulmonary diseases. Chronic obstructive pulmonary disease (COPD) is a disease which progresses in the lungs and requires treatment all through the life. It is an inflammatory disorder which is characterized by obstruction in the variable airflow and airway hyper-responsiveness to many intrinsic, genetic and environmental stimuli. These disorders have become one of the major reasons for disability and death. The prevalence and incidence of this disease is increasing worldwide.

Bronchodilators and polypharmacy dominates the treatment for this disease. It is expected that by 2020, COPD would account for more than 6 Million deaths across the globe annually. Inspite of significant investments in the development of novel agents to treat the disease, the COPD therapy area is generally dominated by inhaled bronchodilator therapies which only relieve symptoms, but do not completely cure the disease. There exist many opportunities for a disease-modifying therapy. However, the development of new COPD therapies is increasingly focusing on therapies which combine two bronchodilators into one inhaler.

Download Report:

https://www.kuickresearch.com/report-COPD-Drug-Market-Opportunity-&-Clinical-Pipeline-Analysis.php

There has been significant expansion in the COPD drug market in the recent years and it is expected that this market would record high growth over the next decade. The major driving force in the future would be a greater demand for new drugs with higher and better efficiency. This market has been recognized to be one with many opportunities which are yet to be tapped. Hence, the leading pharma companies are increasing their focus on this segment by introducing new combination drugs and novel agents. The global market for COPD has been estimated to be close to US$ 12 billion in 2013. With a high number of new and more efficient and convenient drugs crowding the market, it is expected that this market would grow at a CAGR of 8% to reach close to US$ 17.5 billion by 2018.

“COPD Drug Market Opportunity & Clinical Pipeline Analysis” Report Highlight:

* COPD Drug Market Overview
* COPD Patient Base: Global, US & Europe
* FDA & EMA Guidelines on Clinical Investigation of COPD Drugs
* COPD Drug Clinical Pipeline by Phase & Country
* COPD Drug in Development Phase: 174
* Majority of COPD Drugs in Preclinical Phase: 72
* Marketed COPD Drugs: 36
* Discontinued & Suspended COPD Drug Profiles

For Report Sample Contact: neeraj@kuickresearch.com or

visit: https://www.kuickresearch.com

Recent Publications:

* Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022
* Global CAR T Cell Therapy Market & Clinical Trials Insight 2022
* Global Dendritic Cell Cancer Vaccine Market & Clinical Trials Outlook 2023
* Global Microcapsules Drug Delivery Market Opportunity Outlook 2022
* Global Controlled Drug Delivery Market & Clinical Trial Outlook 2022
* Global Cancer Antibody Drug Conjugates Market & Pipeline Insight 2022
* Global B Cell Lymphoma Market & Clinical Pipeline Insight 2022

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.